AU2003292384B2 - Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases - Google Patents

Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases Download PDF

Info

Publication number
AU2003292384B2
AU2003292384B2 AU2003292384A AU2003292384A AU2003292384B2 AU 2003292384 B2 AU2003292384 B2 AU 2003292384B2 AU 2003292384 A AU2003292384 A AU 2003292384A AU 2003292384 A AU2003292384 A AU 2003292384A AU 2003292384 B2 AU2003292384 B2 AU 2003292384B2
Authority
AU
Australia
Prior art keywords
imaging
imaging agent
metal ion
radioactive
msra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003292384A
Other languages
English (en)
Other versions
AU2003292384A1 (en
Inventor
Ian Wilson
Duncan Wynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of AU2003292384A1 publication Critical patent/AU2003292384A1/en
Application granted granted Critical
Publication of AU2003292384B2 publication Critical patent/AU2003292384B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003292384A 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases Ceased AU2003292384B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228490.9 2002-12-06
GBGB0228490.9A GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds
PCT/GB2003/005319 WO2004052357A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Publications (2)

Publication Number Publication Date
AU2003292384A1 AU2003292384A1 (en) 2004-06-30
AU2003292384B2 true AU2003292384B2 (en) 2007-04-19

Family

ID=9949200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292384A Ceased AU2003292384B2 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Country Status (10)

Country Link
US (1) US20060239915A1 (https=)
EP (1) EP1567141A1 (https=)
JP (1) JP2006514945A (https=)
CN (1) CN1744890A (https=)
AU (1) AU2003292384B2 (https=)
CA (1) CA2508663A1 (https=)
GB (1) GB0228490D0 (https=)
NO (1) NO20052633L (https=)
RU (1) RU2005116983A (https=)
WO (1) WO2004052357A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7886497B2 (en) 2003-12-02 2011-02-15 Valinge Innovation Ab Floorboard, system and method for forming a flooring, and a flooring formed thereof
GB0428020D0 (en) 2004-12-22 2005-01-26 Amersham Health As Stabilisation of radiopharmaceutical precursors
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
RU2474435C2 (ru) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Стабилизация радиофармацевтических композиций
US11725395B2 (en) 2009-09-04 2023-08-15 Välinge Innovation AB Resilient floor
EP2473687B1 (en) 2009-09-04 2019-04-24 Välinge Innovation AB A method of assembling resilient floorboards which are provided with a mechanical locking system
PT3115161T (pt) 2011-08-29 2020-02-06 Ceraloc Innovation Ab Sistema de encaixe mecânico para painéis de pavimento
PT3358101T (pt) 2013-03-25 2020-01-21 Vaelinge Innovation Ab Tábuas de piso providas de um sistema de bloqueio mecânico e método para produzir um sistema de bloqueio deste tipo
EP3802514B1 (en) * 2018-06-01 2022-08-03 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2002067761A2 (en) * 2001-02-23 2002-09-06 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
MXPA02000123A (es) * 1999-06-24 2002-07-02 Smithkline Beecham Corp Antagonistas de receptor depurador de macrofago.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2002067761A2 (en) * 2001-02-23 2002-09-06 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Also Published As

Publication number Publication date
JP2006514945A (ja) 2006-05-18
NO20052633D0 (no) 2005-06-01
EP1567141A1 (en) 2005-08-31
CA2508663A1 (en) 2004-06-24
RU2005116983A (ru) 2006-02-27
NO20052633L (no) 2005-07-06
US20060239915A1 (en) 2006-10-26
AU2003292384A1 (en) 2004-06-30
GB0228490D0 (en) 2003-01-08
CN1744890A (zh) 2006-03-08
WO2004052357A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
Mastrostamatis et al. Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents
EP1682113B1 (en) Inhibitor imaging agents
US20070166227A1 (en) Crowned dithiocarbamate metal complexes and methods for their use
KR20100121530A (ko) 관류 영상화를 포함하는 용도를 위한 조영제
US8506932B2 (en) Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR)
AU2003292384B2 (en) Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
US20120244074A1 (en) Labelled integrin binders
US20080124273A1 (en) Novel cationic metal complex radiopharmaceuticals
EP1763371A2 (en) Novel imaging agents comprising caspase-3 inhibitors
AU2004210208B2 (en) Diagnostic imaging agents with MMP inhibitory activity
US20080279769A1 (en) Enzyme Inhibitor Imaging Agents
JP2009518373A (ja) 線維症用の新規造影剤
AU2003273505B2 (en) Improved imaging agents comprising barbituric acid derivatives
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
US20080279771A1 (en) Novel Imaging Agents for Cancer
ITPD20090110A1 (it) Complessi azoturo dissimmetrici monocationici del tecnezio
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired